SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
TXG reported Third Quarter Ended September 30, 2026 results. The stock moved +2.1% on the print.
TXGearnings

Earnings reactions, page 6

10x Genomics, Inc. (TXG) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue was $150.7 million for the third quarter of 2026.
  • Gross margin was 75% for the third quarter of 2026.
  • Operating expenses were $129.0 million for the third quarter of 2026.
  • Operating loss was $16.1 million for the third quarter of 2026.
  • Net loss was $19.4 million for the third quarter of 2026.
  • Cash and cash equivalents and marketable securities were $575.7 million as of September 30, 2026.

Guidance

  • 10x Genomics is raising its full year 2026 revenue guidance and now expects revenue in the range of $625 million to $635 million.

Price and volatility reaction

The stock moved +2.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +2.2 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release58.062026-11-05
Close after release59.282026-11-06
Realised move+2.1%close to close
30d ATM IV change+2.2 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →